The effect of treatment upon temporal dispersion in IvIg responsive multifocal motor neuropathy

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 9, 2005, Pages 1269-1272

  Ghosh, A ^b   Virgincar, A ^a   Kennett, R ^a   Busby, M ^b   Donaghy, Michael ^a,b  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; ELECTROPHYSIOLOGY; ELECTROSTIMULATION; FEMALE; HUMAN; MALE; MOTONEURON; MOTOR NEUROPATHY; MUSCLE ACTION POTENTIAL; NERVE BLOCK; NERVE CONDUCTION; NERVE FIBER; NERVE STIMULATION; PERIPHERAL NERVE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACTION POTENTIALS; ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; ELECTROPHYSIOLOGY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; NEURAL CONDUCTION; TREATMENT OUTCOME;

EID: 23944469575     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.050252     Document Type: Article

References (30)

1. Roth G, Rohr J, Magistris MR, et al. Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Evolution to tetraplegia. Eur Neurol 1986;25:416-23.
2. Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology 1992;42:506-9.
3. Chaudhry V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol 1993;33:237-42.
4. Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1994;57:778-83.
5. Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248-52.
6. Van den Berg-Vos RM, Franssen H, Wokke JH, et al. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol 2000;48:919-26.
7. Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-62.
8. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73-8.
9. Krarup C, Stewart JD, Sumner AJ, et al. A syndrome of asymmetric limb weakness with motor conduction block. Neurology 1990;40:118-27.
10. Feldman EL, Bromberg MB, Albers JW, et al. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 1991;30:397-401.
11. Nobile-Orazio E, Meucci N, Barbieri S, et al. High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology 1993;43:537-44.
12. Cornblath DR, Sumner AJ, Daube J, et al. Conduction block in clinical practice. Muscle Nerve 1991;14:869-71; discussion 867-8.
13. Rhee EK, England JD, Sumner AJ. A computer simulation of conduction block: effects produced by actual block versus interphase cancellation. Ann Neurol 1990;28:146-56.
14. Chaudhry V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: electrodiagnostic features. Muscle Nerve 1994;17:198-205.
15. Oh SJ, Kim DE, Kuruoglu HR. What is the best diagnostic index of conduction block and temporal dispersion? Muscle Nerve 1994;17:489-93.
16. Kafz JS, Wolfe GI, Bryan WW, et al. Electrophysiologic findings in multifocal motor neuropathy. Neurology 1997;48:700-7.
17. Cappellari A, Nobile-Orazio E, Meucci N, et al. Criteria for early detection of conduction block in multifocal motor neuropathy (MMN): a study based on control populations and follow-up of MMN patients. J Neurol 1997;244:625-30.
18. Sumner AJ. Consensus criteria for the diagnosis of partial conduction block and multifocal motor neuropathy. In: Kimura J, Kaji R, eds. Physiology of ALS and related diseases. Amsterdam: Elsevier, 1997:221-7.
19. Olney R. Consensus criteria for the diagnosis of partial conduction block. Muscle Nerve 1999;22:S225-9.
20. Taylor BV, Wright RA, Harper CM, et al. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 2000;23:900-8.
21. Ghosh A, Busby M, Kennett R, et al. A practical definition of conduction block in IvIg responsive multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2005;76:1264-8.
22. Comi G, Amadio S, Galardi G, et al. Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 1994;57(Suppl):35-7.
23. Saperstein DS, Katz JS, Amato AA, et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311-24.
24. Meucci N, Cappellari A, Barbieri S, et al. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 1997;63:765-9.
25. Vucic S, Black KR, Chong PS, et al. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 2004;63:1264-9.
26. Van den Berg-Vos RM, Franssen H, Wokke JH, et al. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002;125:1875-86.
27. Lange DJ, Trojaborg W, Latov N, et al. Multifocal motor neuropathy with conduction block: is it a distinct clinical entity? Neurology 1992;42:497-505.
28. Bouche P, Moulonguet A, Younes-Chennoufi AB, et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 1995;59:38-44.
29. Brown WF, Feasby TE. Conduction block and denervation in Guillain-Barre polyneuropathy. Brain 1984;107:219-39.
30. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994;44:429-32.